Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Expert Rev Hematol
; 16(1): 51-63, 2023 01.
Article
em En
| MEDLINE
| ID: mdl-36620919
MDS are rare bone marrow cancers that lead to low blood counts and carry the risk of disease progression to acute myeloid leukemia. The disease risk (lower vs higher) determines the treatment approach. For lower-risk MDS, the focus has been to improve blood counts and patients' quality of life. Novel treatment strategies are moving earlier in the course of disease to perhaps delay progression. In higher-risk MDS, the goal is to prolong survival and delay progression to acute leukemia. Multiple advanced-phase clinical trials are ongoing to evaluate agents in combination with azacitidine that have shown encouraging results in earlier-phase studies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
/
Leucemia Mieloide Aguda
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos